R1	AND Arg1:T3 Arg2:T2	
R2	AND Arg1:T3 Arg2:T1	
R3	Has_value Arg1:T4 Arg2:T5	
R4	AND Arg1:T1 Arg2:T4	
R5	Has_qualifier Arg1:T7 Arg2:T6	
R6	Has_qualifier Arg1:T8 Arg2:T10	
*	OR T7 T8
R7	Has_qualifier Arg1:T1 Arg2:T7	
R8	Subsumes Arg1:T1 Arg2:T14	
R9	Has_qualifier Arg1:T13 Arg2:T12	
R10	AND Arg1:T12 Arg2:T15	
R11	Has_value Arg1:T17 Arg2:T18	
R12	Has_value Arg1:T19 Arg2:T20	
R13	Has_value Arg1:T22 Arg2:T23	
R14	Has_value Arg1:T24 Arg2:T25	
R15	Has_value Arg1:T26 Arg2:T27	
R16	Has_qualifier Arg1:T26 Arg2:T28	
R17	Has_negation Arg1:T31 Arg2:T32	
R18	Has_index Arg1:T33 Arg2:T34	
R19	Has_temporal Arg1:T31 Arg2:T33	
R20	Has_temporal Arg1:T1 Arg2:T9	
T1	Condition 34 57	glioblastoma multiforme
T2	Procedure 0 17	Histopathological
T3	Observation 0 30	Histopathological verification
T4	Measurement 64 67	WHO
T5	Value 68 76	grade IV
T6	Qualifier 78 90	in remission
T7	Qualifier 92 99	Group A
T8	Qualifier 125 132	Group B
T9	Temporal 109 115	active
T10	Qualifier 104 123	with active disease
T12	Qualifier 136 148	CMV-positive
T13	Condition 149 152	GBM
T14	Condition 59 62	GBM
T15	Condition 136 139	CMV
T16	Condition 154 170	CMV seropositive
T17	Observation 172 187	Life expectancy
T18	Value 188 206	6 weeks or greater
T19	Measurement 208 224	Karnofsky/Lansky
T20	Value 225 244	score 50 or greater
T21	Post-eligibility 246 310	Patient or parent/guardian capable of providing informed consent
T22	Measurement 312 321	Bilirubin
T23	Value 322 358	less than 1.5x upper limit of normal
T24	Measurement 360 363	AST
T25	Value 364 398	less than 3x upper limit of normal
T26	Measurement 468 482	Pulse oximetry
T27	Value 486 500	90% or greater
T28	Qualifier 501 512	on room air
T29	Pregnancy_considerations 514 688	Sexually active patients must be willing to utilize one of the more effective birth control methods for 6 months after the CTL infusion. The male partner should use a condom.
T30	Post-eligibility 690 808	Patients should have been off other investigational antineoplastic therapy for one month prior to entry in this study.
T31	Procedure 742 764	antineoplastic therapy
T32	Negation 711 719	been off
T33	Temporal 765 807	for one month prior to entry in this study
T34	Reference_point 788 807	entry in this study
T35	Post-eligibility 810 935	Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent.
